| 000 | 01623 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250518042354.0 | ||
| 264 | 0 | _c20200618 | |
| 008 | 202006s 0 0 eng d | ||
| 022 | _a1537-4513 | ||
| 024 | 7 |
_a10.1097/CJI.0000000000000271 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBisschop, Cornelis | |
| 245 | 0 | 0 |
_aAssociation Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program. _h[electronic resource] |
| 260 |
_bJournal of immunotherapy (Hagerstown, Md. : 1997) _c |
||
| 300 |
_a208-214 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xadverse effects |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aNetherlands |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aWind, Thijs T | |
| 700 | 1 | _aBlank, Christian U | |
| 700 | 1 | _aKoornstra, Rutger H T | |
| 700 | 1 | _aKapiteijn, Ellen | |
| 700 | 1 | _aVan den Eertwegh, Alfonsus J M | |
| 700 | 1 | _aDe Groot, Jan Willem B | |
| 700 | 1 | _aJalving, Mathilde | |
| 700 | 1 | _aHospers, Geke A P | |
| 773 | 0 |
_tJournal of immunotherapy (Hagerstown, Md. : 1997) _gvol. 42 _gno. 6 _gp. 208-214 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/CJI.0000000000000271 _zAvailable from publisher's website |
| 999 |
_c29745730 _d29745730 |
||